$7.42
-0.64[-7.94%]
At close: May 17
$7.42
0[0.00%]
After Hours: 7:06PM EDT
GoodRx Holdings
(NASDAQ:GDRX)Latest News for GoodRx Holdings Stock (NASDAQ:GDRX)
GoodRx Holdings Stock (NASDAQ: GDRX)
Categories: All
Friday, May 17, 2024
Thursday, May 16, 2024
- Raymond James Upgrades GoodRx Holdings to Outperform, Announces $10 Price TargetBenzinga Newsdesk - 1 day ago
- GoodRx Holdings shares are trading higher after the company on Wednesday announced that it signed a new direct contracting agreement with Kroger. TD Cowen raised its price target on the stock form $14 to $16.Benzinga Newsdesk - 1 day ago
- Forecasting The Future: 13 Analyst Projections For GoodRx HoldingsBenzinga Insights - 1 day ago
- TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $16Benzinga Newsdesk - 1 day ago
Wednesday, May 15, 2024
- GoodRx Shares Soar Nearly 10% As New Partnership With Kroger Promises Big SavingsVaishali Prayag - 2 days ago
- NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - 2 days ago
- GoodRx Holdings shares are trading higher after the company announced that it signed a new direct contracting agreement with Kroger.Benzinga Newsdesk - 2 days ago
- GoodRx Announced A New Direct Contracting Agreement With The Kroger Co. To Deliver Improved Prescription Pricing At More Than 2,200 Kroger Family Pharmacy Locations NationwideBenzinga Newsdesk - 3 days ago
Thursday, May 09, 2024
- Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024Vandana Singh - May 9, 2024, 2:24PM
- GoodRx shares are trading lower after the company issued soft FY24 guidance.Benzinga Newsdesk - May 9, 2024, 9:24AM
- GoodRx Forecasts 2024 Revenue Of $800M-$810M Versus Consensus Of $857.80M, With Adjusted EBITDA Over $250MBenzinga Newsdesk - May 9, 2024, 6:54AM
- GoodRx Forecasts Q2 Revenue Of ~$200M Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent RangeBenzinga Newsdesk - May 9, 2024, 6:52AM
- GoodRx Holdings shares are trading lower following Q1 earnings.Benzinga Newsdesk - May 9, 2024, 6:10AM
- GoodRx Holdings Q1 2024 Adj. EPS $0.08, Inline, Sales $197.880M Beat $196.082M EstimateBenzinga Newsdesk - May 9, 2024, 6:07AM
Wednesday, April 10, 2024
- GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 EarningsPriya Nigam - Apr 10, 2024, 12:10PM
- GoodRx Holdings shares are trading higher after KeyBanc upgraded the stock from Sector Weight to Overweight.Benzinga Newsdesk - Apr 10, 2024, 7:10AM
- Keybanc Upgrades GoodRx Holdings to Overweight, Announces $9 Price TargetBenzinga Newsdesk - Apr 10, 2024, 4:40AM
Monday, March 25, 2024
- Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Mar 25, 2024, 2:44PM
- Telemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst SaysVandana Singh - Mar 25, 2024, 2:00PM
- The Latest Analyst Ratings For GoodRx HoldingsBenzinga Insights - Mar 25, 2024, 11:00AM
- GoodRx Holdings shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and announced a $10 price target.Benzinga Newsdesk - Mar 25, 2024, 7:04AM
- Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market SessionAvi Kapoor - Mar 25, 2024, 5:34AM
- Wells Fargo Upgrades GoodRx Holdings to Overweight, Announces $10 Price TargetBenzinga Newsdesk - Mar 25, 2024, 5:21AM
Friday, March 08, 2024
Friday, March 01, 2024
- Wells Fargo Maintains Equal-Weight on GoodRx Holdings, Raises Price Target to $7.5Benzinga Newsdesk - Mar 1, 2024, 1:01PM
- RBC Capital Maintains Sector Perform on GoodRx Holdings, Raises Price Target to $8Benzinga Newsdesk - Mar 1, 2024, 10:06AM
- Goldman Sachs Maintains Neutral on GoodRx Holdings, Raises Price Target to $7.5Benzinga Newsdesk - Mar 1, 2024, 9:31AM
- Truist Securities Maintains Hold on GoodRx Holdings, Raises Price Target to $8Benzinga Newsdesk - Mar 1, 2024, 8:30AM
- These Analysts Increase Their Forecasts On GoodRx Following Q4 EarningsAvi Kapoor - Mar 1, 2024, 8:23AM
- TD Cowen Maintains Outperform on GoodRx Holdings, Raises Price Target to $14Benzinga Newsdesk - Mar 1, 2024, 8:14AM
- GoodRx Holdings shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $8 to $9. Also, JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $7 to $10.Benzinga Newsdesk - Mar 1, 2024, 7:56AM
- JP Morgan Upgrades GoodRx Holdings to Overweight, Raises Price Target to $10Benzinga Newsdesk - Mar 1, 2024, 6:55AM
- Barclays Maintains Overweight on GoodRx Holdings, Raises Price Target to $9Benzinga Newsdesk - Mar 1, 2024, 6:18AM
Thursday, February 29, 2024
- Why Digital Health Company GoodRx's Shares Are Surging Today?Lekha Gupta - Feb 29, 2024, 11:16AM
- GoodRx Holdings shares are trading higher after the company reported financial Q4 results and issued Q1 revenue guidance above estimates.Benzinga Newsdesk - Feb 29, 2024, 7:17AM
- On February 27, the GoodRx Holdings Board Approved a Buyback Program of up to $450.0MBenzinga Newsdesk - Feb 29, 2024, 6:11AM
- GoodRx Holdings Expects Q1 Adj Revenue of ~$195M-$198M Vs $192.91M Est, FY24 Adj Revenue of ~$800M Vs $790.53M EstBenzinga Newsdesk - Feb 29, 2024, 6:09AM
- GoodRx Holdings Q4 Adj EPS $0.08 Beats $0.07 Estimate, Sales $196.64M Beat $195.83M EstimateBenzinga Newsdesk - Feb 29, 2024, 6:04AM
- Earnings Scheduled For February 29, 2024Benzinga Insights - Feb 29, 2024, 5:15AM
Monday, February 26, 2024
Monday, January 22, 2024
Tuesday, January 16, 2024
Friday, January 12, 2024
Wednesday, January 10, 2024
- Prescription Drug Discount Provider GoodRx Expects To Build Momentum In 2024, Stock SoarsVandana Singh - Jan 10, 2024, 2:00PM
- Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Jan 10, 2024, 1:06PM
- GoodRx shares are trading higher after the company reported preliminary Q4 and FY23 revenues above estimates.Benzinga Newsdesk - Jan 10, 2024, 12:56PM
- GoodRx Sees Prelim. FY23 Adj. Revenue $759M-$761M; Consensus Est. $744.26MBenzinga Newsdesk - Jan 10, 2024, 9:04AM